Abstract:Suxing Liu, 1 Di Li, 1 Jian Liu, 2 Huiyun Wang, 1 Ivana Horecny, 1 Ru Shen, 1 Rumin Zhang, 1 Heping Wu, 2 Qiyue Hu, 3 Peng Zhao, 2 Fengqi Zhang, 2 Yinfa Yan, 2 Jun Feng, 4 Linghang Zhuang, 2 Jing Li, 1 Lianshan Zhang, 5 Weikang Tao 5 1 Department of Biology, Eternity Bioscience Inc., Cranbury, NJ, 08512, USA; 2 Department of Chemistry, Eternity Bioscience Inc., Cranbury, NJ, 08512, USA; 3 Department of Molecular Modeling, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People's Republic of China; 4 Department of Process Chemistry, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People's Republic of China; 5 R&D Center, Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai, 200245, People's Republic of China Correspondence: Suxing Liu Department of Biology, Eternity Bioscience Inc, 6 Cedarbrook Drive, Cranbury, NJ, 08512, USA Email Introduction: CD73 and adenosine support growth-promoting neovascularization, metastasis, and survival in cells, and promote anti-PD-1 mAb therapy-induced immune escape. Consequently, developing a CD73 inhibitor as monotherapy and a potential beneficial combination partner with immune-checkpoint inhibitors needs investigation. Methods: CD73 inhibitors were evaluated in vitro with soluble and membrane-bound CD73 enzymes, as well as its PD biomarker responses in human peripheral blood mononuclear cells (PBMC) by flow cytometry and ELISA. The binding modes of the molecules were analyzed via molecular modeling. The anti-tumor activity and synergistic effect of SHR170008 in combination with anti-PD-1 mAb were evaluated in a syngeneic mouse breast cancer model. Results: SHR170008 was discovered during the initial structural modifications on the link between the ribose and the α-phosphate of AMPCP, which significantly improved the stability of the compound confirmed by the metabolite identification study. Further modifications on the adenine base of AMPCP improved the potency due to forming stronger interactions with CD73 protein. It exhibited potent inhibitory activities on soluble and endogenous membrane-bound CD73 enzymes, and induced IFNγ production, reversed AMP-suppressed CD25 + and CD8 + /CD25 + expression, and enhanced granzyme B production on CD8 + T cells in human PBMC. SHR170008 showed dose-dependent anti-tumor efficacy with suppression of adenosine in the tumors in EMT6 mouse breast tumor model. The increase of adenosine in tumor tissue by anti-PD-1 mAb alone was suppressed by SHR170008 in the combination groups. Simultaneous inhibition of CD73 and PD-1 neutralization synergistically enhanced antitumor immunity and biomarkers in response, and exposures of SHR170008 were correlated with the efficacy readouts. Conclusion: Our findings suggest that CD73 may serve as an immune checkpoint by generating adenosine, which suppresses the antitumor activity of anti-PD-1 mAb, and inhibition of CD73 may be a potential beneficial combination partner with immune-checkpoint inhibitors to improve their therapeutic outcomes in general. Keywords: small-molecule inhibitor of CD73, adenosine, anti-PD-1 mAb, checkpoint blockade, immunotherapy, combination therapy Here we described SHR170008, a novel and potent small-molecule inhibitor of CD73. An outstanding feature of SHR170008 different from AMPCP is that the bisphosphonic acid was replaced by methylenephosphonic acid, which significantly improved the stability of the compound confirmed by the metabolite identification study. Furthermore, SHR170008 not only could rescue the inhibitory effect of adenosine derived from AMP in the activation and proliferation of CD8 + T cells and granzyme B production in human primary immune cells but also exhibited dose-dependent tumor growth inhibition in single agent and significantly enhanced the efficacy in combination with anti-PD-1 mAb in EMT6 mouse breast tumor model. PD-1 blockade resulted in enhanced adenosine levels in tumor as compared with the control group and decreased adenosine levels in combination with SHR170008. Our findings extended the understanding of adenosine generated by CD73 in suppressing antitumor immunity, which contributed to the resistance of PD-1 checkpoint inhibition. Results from further clinical evaluation of this specific mechanism for immunotherapy of cancer, especially in combination with monoclonal antibody therapies targeting immune checkpoints are highly anticipated. T cell-mediated anti-tumor immune responses are pivotal for effective ablation of primary tumor lesions and for protection aga -Abstract Truncated-

Abstract LB166: Discovery of CT3021, a novel potent adenosine A2a/A2b/A1 receptor triple antagonist

Abstract 2337: The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1

POTENT AND SELECTIVE A2AR MONOCLONAL ANTIBODY ANTAGONIST FOR THE TREATMENT OF CANCER

AB928, a Dual Antagonist of the A2aR and A2bR Adenosine Receptors, Leads to Greater Immune Activation and Reduced Tumor Growth when Combined with Chemotherapy

Discovery of Pyridinone Derivatives As Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Abstract 2459: ADT-030 is a novel dual-acting RAS/β-catenin inhibitor that potentiates antitumor immunity

Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist

Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8h)-one Derivatives As Novel Potent Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Abstract 3095: Development of a novel ADAR1 inhibitor as a potent immunomodulator for the treatment of solid tumors

A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer

Abstract 734: Inhibition of equilibrative nucleoside transporter 1 relieves intracellular adenosine-mediated immune suppression

Abstract 4135: A novel plasma cell-based mechanism of action of adenosine immunomodulation and A2AR antagonism

Dual A2A/ A2B adenosine receptor antagonist M1069 counteracts immuno-suppressive mechanisms of adenosine and reduces tumor growth in vivo

Adenosine A2B receptor blockade slows growth of bladder and breast tumors

Structural Insight into the Dual-Antagonistic Mechanism of AB928 on Adenosine A2 Receptors.

Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles

Structural Insights into Dual-Antagonize Mechanism of AB928 on Adenosine A2receptors

Abstract LB348: Discovery and in vitro efficacy validation of anti-CD39 monoclonal antibody for improving the tumor microenvironment

Abstract 5907: Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-317 targeting NaPi2b

Abstract 1853: A Novel Anti-Ctla-4 Checkpoint Inhibitor Prodrug to Address On-Target Off-Tumor Toxicity for Cancer Immunotherapy

Abstract 5099: Anti-tumor effect of DA-4505, a novel AhR antagonist as an immunotherapy in the tumor microenvironment